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Abstract
Background: A decrease in pulmonary surfactant has been suggested to contribute to the lung
dysfunction associated with pulmonary inflammation. A number of studies have implicated
surfactant clearance as a possible mechanism for altered pool sizes. The objective of the current
study was to specifically investigate the mechanisms of surfactant clearance in a rodent model of
acute pulmonary inflammation.
Methods: Inflammation was induced by intrapulmonary instillation of lipopolysaccharide (LPS: 100
µg/kg). Lipid clearance was assessed at 18 and 72 hours post-LPS instillation by intratracheal
administration of radiolabel surfactant-like liposomes 2 hours prior to isolation and analysis of
inflammatory cells and type II cells.
Results: At both 18 and 72 hours after LPS instillation there was significantly less radioactivity
recovered in the lavage fluid compared to respective control groups (p < 0.05). At both time points,
the number of cells recovered by lavage and their associated radioactivity was greater compared
to control groups (p < 0.01). There was no difference in recovery of radioactivity by isolated type
II cells or other cells obtained from enzymatic digestion of lung tissue.
Conclusion: These results show that increased clearance of surfactant lipids in our model of acute
pulmonary inflammation is primarily due to the inflammatory cells recruited to the airspace and not
increased uptake by alveolar type II cells.
Background
Pulmonary surfactant is a phospholipid-protein complex
that lines the inner surface of the lung and is essential for
normal pulmonary function. Surfactant acts to promote
lung stability by reducing surface tension within the lung,
while also protecting against inhaled pathogens. Sur-
factant is composed of approximately 90% lipids and
10% proteins by weight. The lipid component is primarily
phospholipids with phosphatidylcholine (PC) being the
most abundant, and the protein component comprised of
four surfactant-associated proteins designated SP-A, SP-B,
SP-C and SP-D [1]. The reduction of surface tension
within the lung is a result of the interaction between sur-
factant phospholipids and the two hydrophobic sur-
factant proteins, SP-B and SP-C [1], while the two
hydrophilic proteins, SP-A and SP-D, are members of a
family of innate immune molecules called collectins [2].
Collectins opsonize bacteria and viruses and enhance
their phagocytosis by macrophages and neutrophils [2].
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Alterations of the pulmonary surfactant system, including
decreased total surfactant levels, have been implicated in
the pathophysiology of acute lung injury. Multiple studies
of patients with a variety of lung diseases have shown that
surfactant levels are decreased in the inflamed, injured, or
infected lung [3-5]. In agreement, decreases in alveolar
surfactant lipid pools have also been observed in several
animal models of lung inflammation induced by both
direct insults to the lung, such as bacterial infection [6],
oxygen toxicity [7,8], endotoxin administration [9-11],
and by indirect insults, such as N-nitroso-N-methyl-
urethane [12] and cecal ligation and perforation [13].
Alveolar metabolism of surfactant is a complex process,
primarily involving type II epithelial cells that synthesize,
secrete and clear surfactant from the airspaces [14], along
with phagocytic cells such as macrophages and neu-
trophils that participate in surfactant clearance [15,16]. In
a situation of pulmonary inflammation, altered type II
cell metabolism has been thought to play a role in the
alterations of surfactant lipid levels. Viviano et al.
observed a decrease in alveolar surfactant levels and a cor-
responding increase in intracellular surfactant after
lipopolysaccharide (LPS) administration [10]. Addition-
ally, exposure of rat lungs ventilated ex vivo to LPS resulted
in the presence of giant lamellar bodies within the type II
cells [17,18]. Collectively these studies suggest that type II
cell metabolism is altered after LPS administration and
that a possible explanation for decreased surfactant pool
size may be increased clearance of surfactant lipids by the
type II cells. Additional experimental evidence has also
implicated recruited inflammatory cells as having an
impact on surfactant pool sizes. Both neutrophils and
macrophages recovered from LPS exposed lungs had a
greater capacity to internalize surfactant-like lipids com-
pared to control cells in vitro [16]. Therefore these
recruited inflammatory cells may also have a significant
impact on surfactant pool size by increasing the overall
surfactant lipid clearance.
The objective of the current study was specifically to inves-
tigate the mechanisms of in vivo surfactant clearance in a
rodent model of acute pulmonary inflammation induced
by intrapulmonary instillation of LPS. We hypothesized
that during pulmonary inflammation there is altered
clearance of alveolar phospholipid by both alveolar type
II cells and inflammatory cells within the airspaces. We
analyzed in vivo clearance of surfactant lipids by a variety
of pulmonary cells at 18 and 72 hours after LPS instilla-
tion. Results indicated that increased clearance of sur-
factant lipids in our model of acute pulmonary
inflammation is primarily due to enhanced lipid uptake
by the inflammatory cells recruited to the airspace,
whereas uptake by type II cells was unaltered. However
the in vivo surfactant uptake by inflammatory cells in the
current study was significantly less than that predicted by
previous in vitro studies [16].
Methods
Materials
Dipalmitoylphosphatidylcholine (DPPC), egg phosphati-
dylcholine (PC), dipalmitoylphosphatidylglycerol
(DPPG) and cholesterol were purchased from Avanti
Polar Lipids (Birmingham, AL). L-α-dipalmitoyl [2-
palmitoyl-9,10-3H(N)]PC was obtained from DuPont
New England Nuclear (Boston, MA). Elastase for type II
cell isolations was purchased from Worthington Bio-
chemicals (Freehold, NJ). Dulbecco's PBS, DMEM, and
fetal bovine serum (FBS) were obtained from Life Tech-
nologies (Gaithersburg, MD). Low-endotoxin BSA,
O26:B6 Escherichia coli LPS, Rat IgG and all other chemi-
cals were purchased from Sigma (St. Louis, MO). Chloro-
form and methanol were obtained from EM Science
(Gibbstown, NJ).
Preparation of Liposomes
Small unilamellar liposomes were prepared with a lipid
composition similar to pulmonary surfactant: 52% DPPC,
26% egg PC, 15% DPPG and 7% cholesterol by weight
with trace amounts of 3H-DPPC (12 µCi/mg phospholi-
pid). The lipids were dried under nitrogen, reconstituted
in 0.15 M saline and extruded from a French Press cell
under 900 psi. This resulted in small unilamellar lipo-
somes at a concentration of approximately 1 mg lipid/ml.
Animal Model
Male pathogen-free Sprague Dawley rats (150–200 g;
Taconic Farms, Germantown, NY) were used for the cur-
rent study. For LPS animals, endotoxin (0.1 mg/kg of
O26:B6 E. coli LPS) was suspended in 300 µl of sterile 0.15
M saline. Control animals received an equal volume (300
µl) of sterile 0.15 M saline. For instillation, animals were
anesthetized with halothane such that they remained
unconscious throughout the entire instillation procedure
and had no cough reflex upon intubation. Animals were
placed on a board at a 45° angle, intubated with an 18-
gauge blunt ended catheter and either sterile saline or LPS
suspension was instilled followed by five 1 ml boluses of
air to facilitate the distribution of the instilled fluid. Two
hours prior to killing, liposomes (100 µg lipid) were
intratracheally instilled in all groups following the identi-
cal instillation procedure. Separate groups of both control
and LPS animals were sacrificed at 18 or 72 hours after
saline or LPS instillation.
Whole Lung Studies
One control animal and one LPS animal were investigated
simultaneously, thus all procedures were done in parallel.
At 18 or 72 hours after saline or LPS instillation, animals
were anesthetized with 0.3 mg of sodium pentobarbitalRespiratory Research 2004, 5:8 http://respiratory-research.com/content/5/1/8
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and 700 U of heparin. After loss of toe pinch reflex, the
trachea was cannulated and the rat was exsanguinated via
transection of the descending aorta. The chest cavity was
subsequently opened and the lungs perfused through the
pulmonary artery with 40–50 ml of a calcium buffer (140
mM NaCl, 5 mM KCl, 2.5 mM Na2HPO4, 10 mM HEPES,
2.0 mM CaCl2, and 1.3 mM MgSO4 at 37°C). The lung
from the first animal was carefully removed from the tho-
racic cavity and placed between saline soaked gauze pads
while the second lung was perfused and removed in iden-
tical fashion. The time for lung perfusion and removal was
approximately 10 minutes. After lungs were isolated from
both a control and LPS animal, they were lavaged simul-
taneously with eight 10-ml volumes of EGTA buffer (140
mM NaCl, 5 mM KCl, 2.5 mM Na2HPO4, 10 mM HEPES,
and 0.2 mM EGTA at 37°C). For each animal the individ-
ual lavages were collected and combined to make up the
bronchoalveolar lavage fluid (BALF), which was immedi-
ately stored on ice. After the lavage procedure, individual
lobes were dissected away from the major airways. The
lung tissue was then cut into 5 mm pieces in 5 ml calcium
buffer and subsequently homogenized with a Polytron
PT-MR-2100. After complete homogenization, total lung
tissue volume was diluted to 40 ml with calcium buffer
and stored on ice. A small aliquot (2 ml) of the total BALF
was removed and the remainder was centrifuged at 250 g
for 10 minutes at 4°C to generate a pellet that was prima-
rily BALF cells. The cell pellet was subsequently suspended
in 10 ml of PBS. Lavage cell numbers were determined by
a hemocytometer, viability determined by trypan blue
exclusion and cell differential determined by Hemacolor
staining of cytospins that were prepared using a Shandon
Cytospin 2 centrifuge. Liposome-association in total
BALF, cell-free BALF, BALF cells and homogenized lung
tissue was determined by scintillation counting.
Surfactant Phospholipid Measurement
Alveolar phospholipid levels were measured in the cell-
free BALF by phospholipid-phosphorous measurement.
Lipids were extracted using the method of Bligh & Dyer
[19] and phospholipid levels were determined using a
modification of the Duck-Chong phosphorous assay [20].
Briefly, 100 µl of 10% magnesium nitrate in methanol
was added to the extracted lipids. After drying, the sam-
ples were ashed in a fume hood on an electric rack for
approximately 1 min. After 1 ml of 1 M HCl was added,
the samples were reheated on a heating block while cov-
ered for 15 min at 95°C. After cooling, a 66 µl aliquot of
each sample was added to individual wells of a 96 well
plate along with 134 µl of a dye consisting of 4.2% ammo-
nium molybdate in 4.5 M HCl with 0.3% malachite green
(1:3 vol/vol). The absorbency of each sample was read at
650 nm using a Biorad 550 microplate reader and com-
pared to reference standards on the same plate.
Surfactant Protein A (SP-A) Analysis
Relative quantities of alveolar SP-A from 18-hour control
animals, 18-hour LPS animals and 72-hour LPS animals
were determined by loading equal volumes of BALF on
15% SDS-PAGE gels under reducing conditions. Total
BALF recovery was not different among the individual ani-
mals. Proteins were then transferred to nitrocellulose
where SP-A was probed with a well characterized polyclo-
nal rabbit anti-rat SP-A [21]. The nitrocellulose was subse-
quently developed using the ECL system (Amersham
Pharmacia Biotech, Piscataway, NJ).
Type II Cell Isolation
A separate cohort of animals was required for type II cell
isolation studies. As with the whole lung studies, type II
cell isolation was completed for one control and one LPS
rat in parallel for both 18- and 72-hour time points after
instillation of saline or LPS. The type II cell isolation pro-
cedure was described previously with minor modifica-
tions of the original protocol [22,23]. The modifications
were designed for isolation of type II cells from inflamed
lungs, and included increasing the elastase to 3,000 orcein
units/lung, and increasing the surface area for IgG pan-
ning by two-fold. Briefly the isolation procedure involved
killing the rats, removing the lungs and lavaging the lungs
eight times as stated in Whole Lung Studies. Subsequently
the lungs were lavaged twice with calcium buffer (37°C)
and once with elastase solution (3000 orcein/40 ml cal-
cium buffer; 37°C). The lungs were then filled with the
elastase solution and suspended in warmed saline (37°C)
for 20 minutes. Lung tissue was removed from the major
airways, cut into 5-mm pieces and chopped 200 times
with sharp scissors in 5 ml of the calcium solution along
with 2 mg of DNase. The tissue suspension was added to
a flask with 4 ml of FBS and 35 ml of calcium buffer and
shaken vigorously for 2 min in a 37°C water bath. The
resultant tissue suspension was strained through gauze,
and then decreasing sizes of nylon mesh (150-, 15-, and
8-µm). The cell suspension was centrifuged at 250 g for 10
min at 4°C, the resulting cellular pellet was suspended in
20 ml of warm DMEM (37°C) and incubated on two IgG
coated Petri dishes (150 × 15 mm) for 30 minutes at
37°C. After the incubation period, nonadherent cells were
removed from the plate, washed once with PBS, sus-
pended in calcium buffer and used for determination of
radiolabel recovery associated with Type II cells. The
remaining adherent cells were gently scraped off the plate
in 5 ml of DMEM and transferred into a polypropylene
tube; this population of cells is referred to as "plate cells"
and consisted primarily of macrophages and/or neu-
trophils as described in detail below. The cells were
washed once and suspended in calcium buffer for deter-
mination of associated radioactivity. A small aliquot from
the isolated type II cells and plate cells was saved for dif-
ferential cell count and viability. Cell purity wasRespiratory Research 2004, 5:8 http://respiratory-research.com/content/5/1/8
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determined by counting a minimum of 250 cells from
random fields after staining by the Papanicolaou method
[22].
Statistics
All data reported are means ± standard error (SE). Repeti-
tions (n) used to calculate means ± SE were from inde-
pendent experiments, not from replicates within an
experiment. An analysis of variance (ANOVA) was used to
determine differences between all experimental groups at
a specific time point, followed by a Tukey post-hoc test for
multiple comparisons. Significance was accepted when p
< 0.05.
Results
LPS-induced alterations: BALF cells and alveolar 
surfactant
Table 1 reveals total alveolar cell numbers and differen-
tials from the BALF of control and LPS groups killed at the
18- and 72-hour time points. Eighteen hours after instilla-
tion of LPS there were significantly more cells recovered in
the BALF from the LPS treated animals compared to the
saline control group (p < 0.01). Cell differentials from the
two 18-hour groups revealed that the LPS group had pri-
marily neutrophils in the BALF, whereas the cells recov-
ered from the control group were predominantly
macrophages. Seventy-two hours after LPS instillation
there were significantly greater numbers of cells in the
BALF of the LPS group compared to the 72-hour control
group (p < 0.01), but significantly fewer numbers of cells
compared to the LPS 18-hour group (p < 0.01). Cell dif-
ferentials from the 72-hour groups revealed that the cells
were predominately macrophages in both the LPS and
control groups. Of note, there were no differences in cell
numbers or differentials between the two control groups
at the different time points.
Table 1 also displays the total phospholipid levels meas-
ured in the BALF of the four experimental groups. There
was an approximate 15% decrease in total phospholipid
recovered by lung lavage from both LPS groups compared
to their respective saline control groups, however this did
not reach statistical significance. Of note, there was no dif-
ference in mean body weights among the four experimen-
tal groups (Con 18: 177 ± 7 g; LPS 18: 180 ± 10 g; Con 72:
186 ± 9 g; LPS 72: 192 ± 7 g). Figure 1 shows Western blot
analysis of SP-A measured in the BALF recovered from ani-
mals killed 18 hours post saline instillation (control), and
18 hours and 72 hours after LPS instillation. There was rel-
atively greater quantity of SP-A in the BALF of animals
killed at both 18 and 72 hours after LPS instillation com-
pared to the control animals, consistent with previous
reports using similar models of intrapulmonary LPS
administration [9-11].
Whole Lung Studies: Clearance of Radiolabel Liposomes
Figure 2 shows distribution of the recovered radioactivity
associated with the cell free BALF, the isolated BALF cells,
and whole lung tissue for the two groups killed 18 hours
after instillation of saline or LPS. There was no difference
in total lung radioactivity recovered compared to the total
radiolabel instilled between the Control 18 and LPS 18
Table 1: Bronchoalveolar lavage fluid characteristics from animals killed 18 and 72 hours after instillation of saline (Control) or 
lipopolysaccharide (LPS).
Control 18 (n = 6) LPS 18 (n = 6) Control 72 (n = 6) LPS 72 (n = 6)
Cell Numbers (106) 12.3 ± 1.1 102.8 ± 8.1* 11.3 ± 0.9 57.3 ± 6.6*#
% Macrophages 98.2 ± 0.3 7.3 ± 0.8* 97.7 ± 0.4 90 ± 1.5*
% Neutrophils 1.8 ± 0.3 92.7 ± 0.8* 2.3 ± 0.4 10 ± 1.5*
Alveolar Phospholipid (mg PL/kg BW) 14.7 ± 0.7 12.8 ± 0.9 14.0 ± 0.4 12.9 ± 0.5
Abbreviations: PL = phospholipid; BW = body weight. Values are mean ± SEM. * = p < 0.01 vs. appropriate control; # = p < 0.01 vs. LPS 18.
Alveolar surfactant protein A (SP-A) levels Figure 1
Alveolar surfactant protein A (SP-A) levels. Relative 
quantities of alveolar SP-A were measured by Western Blot. 
Equal volumes of bronchoalveolar lavage fluid (BALF) from 
the individual animals were utilized and total BALF recovery 
was not different among these animals. Lanes 1 and 2 repre-
sent individual animals that were lavaged 18 hours after saline 
instillation. Lanes 3 and 4 represent individual animals that 
were lavaged 18 hours after instillation of 100 µg/kg O26:B6 
lipopolysaccharide (LPS). Lanes 5 and 6 represent animals 
lavaged 72 hours after instillation of 100 µg/kg 026:B6 LPS.
Control LPS 18 LPS 72
1 23456
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groups (46.0 ± 4.6% and 48.4 ± 4.0%; respectively). There
was significantly less radiolabel recovered in the BALF (p
< 0.05) and significantly more radiolabel associated with
the BALF cells (p < 0.01) in the LPS group compared to the
control group. There was no difference in radiolabel asso-
ciation with lung tissue between the two groups.
Figure 3 displays total recovered radioactivity associated
with the cell free BALF, the isolated BALF cells, and whole
lung tissue for the two groups killed 72 hours after instil-
lation of saline or LPS. There was no difference in the total
lung radiolabel recovered compared to the total radiola-
bel instilled between the Control 72 and LPS 72 groups
(47.3 ± 4.0% and 44.8 ± 3.8%; respectively). There was
significantly less radiolabel recovered in the BALF (p <
0.05) and significantly more radiolabel liposomes associ-
ated with the BALF cells (p < 0.01) in the LPS group com-
pared to the control group. There was no difference in
radiolabel associated with lung tissue between the two
groups.
Additional controls were performed in which animals (n
= 2) received radiolabel liposomes followed by whole
lung lavage and lung tissue homogenization 5 minutes
after the instillation procedure. Mean total lung radiolabel
recovery for this control group was 77% suggesting that
~25% of the radiolabel liposomes were lost in the instilla-
tion procedure (i.e., syringe, catheter), or possibly were
adhered to the airway epithelium. The distribution of the
recovered liposomal radioactivity within the 5-minute
control lungs was 91% associated with the BALF, 2% asso-
ciated with BALF cells, and 7% associated with lung tissue.
Type II Cell Isolation: Cell Recoveries, Purities and 
Radioactivity per Cell
Table 2 demonstrates the cell recovery and cell differential
after type II cell isolation for the two experimental groups
at the 18-hour time point. Type II cell recovery for the con-
trol group ranged from 10.4 × 106 to 21.6 × 106 cells with
a mean of 17.1 × 106. The purity of this cell fraction aver-
aged greater than 80% type II cells and viability was
greater than 95%. Plate cell recovery from the control
group ranged from 1.8 × 106 to 4.7 × 106 cells with a mean
value of 3.2 × 106. This cell fraction was predominately
macrophages and the viability was greater than 90%. For
the LPS group at the 18-hour time point, type II cell
Distribution of radiolabel liposomes 18 hours after instilla- tion of LPS Figure 2
Distribution of radiolabel liposomes 18 hours after 
instillation of LPS. Whole lung distribution of the total 
recovered 3H-liposomes instilled 2 hours prior to killing. Ani-
mals were killed 18 hours after instillation of saline (Con 18) 
or 100 µg/kg O26:B6 lipopolysaccharide (LPS 18) where the 
lungs were lavaged, lavage cells isolated and whole lung tissue 
homogenized. Radioactivity was subsequently measured in 
cell free bronchoalveolar lavage fluid (BALF), isolated BALF 
cells and whole lung tissue homogenate (Tissue). Data are 
means ± SEM and expressed as a percentage of total recov-
ered radiolabel; n = 6 animals/group. Statistical significance * 
= p < 0.05 vs. respective control group.









































Distribution of radiolabel liposomes 72 hours after instilla- tion of LPS Figure 3
Distribution of radiolabel liposomes 72 hours after 
instillation of LPS. Whole lung distribution of the total 
recovered 3H-liposomes instilled 2 hours prior to killing. Ani-
mals were killed 72 hours after instillation of saline (Con 72) 
or 100 µg/kg O26:B6 lipopolysaccharide (LPS 72) where the 
lungs were lavaged, lavage cells isolated and whole lung tissue 
homogenized. Radioactivity was subsequently measured in 
cell free bronchoalveolar lavage fluid (BALF), isolated BALF 
cells and whole lung tissue homogenate (Tissue). Data are 
means ± SEM and expressed as a percentage of total recov-
ered radiolabel; n = 6 animals/group. Statistical significance * 
= p < 0.05 vs. respective control group.
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recovery ranged from 10.6 × 106 to 20.5 × 106 cells and a
mean of 16.3 × 106 cells, with a purity greater than 85%
type II cells and viability greater than 95%. Plate cells
from the LPS 18 group ranged from 2.7 × 106 to 13 × 106
cells with a mean of 6.6 × 106 cells. This cell population
consisted primarily of neutrophils and macrophages and
viability was greater than 90%. There were no significant
differences in cell numbers obtained from control and
LPS animals 18 hours after saline or LPS instillation.
Figure 4 reveals the radioactivity per million tissue cells
for the isolated type II cells and the other tissue associated
cells (plate cells) for the control and LPS 18-hour groups.
There were no significant differences in the radioactivity
per type II cell or plate cell between the control group and
the LPS group at the 18-hour time point after instillation.
Table 3 shows the cell recovery and cell differential after
type II cell isolation for the two experimental groups at the
72-hour time point. Type II cell recovery for the control
group ranged from 21.2 × 106 to 40 × 106 cells with a
mean of 28.4 × 106. The purity of this cell fraction aver-
aged 75% type II cells and viability was greater than 95%.
The number of cells obtained from the plate group ranged
from 1.8 × 106to 15.9 × 106 cells with a mean value of 6.2
× 106 with the primary cell type being macrophages with
a small percentage of neutrophils and type II cells.
Viability for the plate cells were greater than 90%. For the
LPS group at the 72-hour time point, type II cell recovery
ranged from 19.2 × 106 to 64.6 × 106 cells and a mean of
33.2 × 106 cells, purity greater than 80% type II cells and
viability greater than 95%. Plate cells from the LPS 18-
hour group ranged from 3.3 × 106 to 16.2 × 106 cells with
a mean of 7.8 × 106 cells. This cell population consisted
primarily of macrophages and viability was greater than
90%. There were no significant differences in cell recover-
ies between the control and LPS groups at the 72-hour
time point. Of note, there were a greater number of cells
recovered from both 72-hour groups compared to both
18-hour groups.
Figure 5 reveals the radioactivity per million tissue cells
for the isolated type II cells and the other tissue-associated
cells (plate cells) for the control and LPS 72-hour groups.
There were no significant differences in the radioactivity
per type II cell or plate cell between the LPS group and the
control group 72 hours after the appropriate instillation.
Of note there was no significant difference in radioactivity
per cell for both the type II cells and plate cells between
the two 72-hour groups and the two 18-hour groups.
Table 2: Cell recovery and differential after lung digestion and IgG panning for animals killed 18 hours after instillation of saline (Control) 
or lipopolysaccharide (LPS).
Control 18 (n = 7) LPS 18 (n = 7)
Type II Cells Plate Cells Type II Cells Plate Cells
Cell Numbers (106) 17.1 ± 1.6 3.2 ± 0.5 16.3 ± 1.8 6.6 ± 1.7
% Type II 81 ± 2 15 ± 7 86 ± 2 14 ± 2
% Macrophages 9 ± 1 61 ± 5 3 ± 1* 33 ± 2*
% Neutrophils 1 ± 1 17 ± 10 4 ± 1 53 ± 3*
% Other Cells 9 ± 2 7 ± 2 7 ± 2 -
Values are mean ± SEM. * = p < 0.01 vs. Control.
Liposome uptake by lung tissue cells 18 hours after instilla- tion of LPS Figure 4
Liposome uptake by lung tissue cells 18 hours after 
instillation of LPS. Association of 3H-liposomes instilled 2 
hours prior to killing in cells isolated from lung tissue. Ani-
mals were killed 18 hours after instillation of saline (Con 18) 
or 100 µg/kg O26:B6 LPS (LPS 18). Lungs were lavaged and 
type II cells and other tissue-associated cells (plate cells) 
were isolated. Data are means ± SEM and expressed as DPM/
106 cells, n = 7 animals/group.
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Discussion
In the present study, we evaluated the clearance of sur-
factant-like liposomes at 18 and 72 hours following the
intrapulmonary instillation of LPS. At both time points,
radiolabel liposomes were instilled two hours prior to
killing and the distribution within the lung was deter-
mined. Radioactivity was measured in cell-free BALF, iso-
lated BALF cells, whole lung tissue, isolated type II cells
and remaining tissue-associated cells. At both time points
there was a significant increase in clearance of exogenous
liposomes from the airspace and a small decrease in alve-
olar surfactant phospholipid levels in the LPS groups
compared to control groups that received vehicle only.
This corresponded with increased radiolabel associated
with isolated BALF cells and no difference associated with
lung tissue at either time point after LPS instillation
compared to controls. There was no difference in lipo-
somal radioactivity associated with isolated type II cells or
other tissue cells between both LPS groups and their
respective control groups, which was in agreement with
whole lung measurements. These data suggest that cells
recruited into the airspace as a consequence of the LPS-
induced inflammatory response can significantly contrib-
ute to increased clearance of surfactant-like liposomes
from the airspace (Figs. 2 and 3).
Eighteen hours after LPS instillation there was an infiltra-
tion of neutrophils into the airspace which resulted in a
10-fold increase in BALF cells. At this time point there was
a doubling of total liposomal radioactivity associated with
these inflammatory cells compared to alveolar cells recov-
ered from control animals. Neutrophils recruited into
alveolar spaces during infection are essential for host
defense by phagocytosis and killing of bacteria and other
infectious agents. Previous studies have documented that
surfactant can in fact modulate neutrophil functions, as
surfactant proteins A and D can enhance neutrophil
uptake of bacteria [24]. Although these phagocytic cells
are extremely important in host defense, they have also
been implicated as a contributing factor to the lung injury
in a variety of inflammatory disorders. In a recent study by
Quintero et al., it was demonstrated by confocal micros-
copy that neutrophils isolated from inflamed lungs were
able to significantly internalize and degrade surfactant
lipids in vitro [16]. Based on in vitro measurements of lipid
uptake, they estimated that neutrophils could account for
Table 3: Cell recovery and differential after lung digestion and IgG panning for animals killed 72 hours after instillation of saline (Control) 
or lipopolysaccharide (LPS).
Control 72 (n = 6) LPS 72 (n = 7)
Type II Cells Plate Cells Type II Cells Plate Cells
Cell Numbers (106) 28.4 ± 3.9 6.2 ± 2.2 33.2 ± 5.6 7.8 ± 2.2
% Type II Cells 75 ± 2 22 ± 3 83 ± 1 19 ± 3
%  M a c r o p h a g e s 1 1  ±  25 6  ±  51 2  ±  25 9  ±  4
% Neutrophils - 22 ± 7 2 ± 1 22 ± 3
% Other Cells 14 ± 1 - 3 ± 3* -
Values are mean ± SEM. * = p < 0.01 vs. Control.
Liposome uptake by lung tissue cells 72 hours after instilla- tion of LPS Figure 5
Liposome uptake by lung tissue cells 72 hours after 
instillation of LPS. Association of 3H-liposomes instilled 2 
hours prior to killing in cells isolated from lung tissue. Ani-
mals were killed 72 hours after instillation of saline (Con 72) 
or 100 µg/kg O26:B6 LPS (LPS 72). Lungs were lavaged and 
type II cells and other tissue-associated cells (plate cells) 
were isolated. Data are means ± SEM and expressed as DPM/
106 cells; Con 72 = 6 animals, LPS 72 = 7 animals.
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up to 48% of the observed clearance and could signifi-
cantly impact surfactant homeostasis. Data from the cur-
rent study supports this idea by demonstrating that in vivo,
neutrophils can indeed contribute to the clearance of sur-
factant lipids during pulmonary inflammation.
At the 72-hour time point after LPS instillation there was
an accumulation of macrophages in the alveolar space
that resulted in a 5-fold increase in BALF cells compared
to control animals. There was a doubling of radiolabeled
phospholipids associated with these alveolar cells and no
increase in the amount of radiolabeled phospholipids
associated with whole lung tissue. This resulted in a
significant increased in clearance of total liposomal radio-
activity from the BALF, 72 hours after LPS instillation.
Alveolar macrophages have been shown in vitro to take up
and degrade surfactant lipids and have also been shown in
vivo to account for approximately 20% of surfactant lipid
clearance in normal lungs [16,25]. Macrophages isolated
from LPS-exposed lungs were shown to have a greater
capacity to take up surfactant lipids in vitro than macro-
phages isolated from normal lungs [16], suggesting that in
an inflamed lung, the recruited macrophages may have a
significant role in surfactant metabolism. Indeed, the in
vivo data presented in the current study support the theory
that activated alveolar macrophages can impact clearance
of surfactant lipids.
Of note, previous in vitro data had predicted that inflam-
matory cells (neutrophils and macrophages) could
account for a 6 to 13 fold increase in lipid clearance [16].
In the current study there was a 5–10 fold increase in alve-
olar inflammatory cells but only a doubling of cell associ-
ated radioactivity and a change in alveolar phospholipid
pool size of approximately 15%. Importantly, the current
study instilled a similar dose of LPS, had similar end
points and the same number of inflammatory cells recov-
ered from the BALF as the aforementioned in vitro study.
Although the present in vivo data demonstrated that the
inflammatory cells can indeed contribute to increased
lipid clearance as suggested previously, the absolute value
was considerably less than that predicted from the in vitro
studies. Although we do not have an explanation for this
quantitative difference between the in vivo and in vitro
observations, it is possible that the process of cell isola-
tion in the in vitro study resulted in their activation for
subsequent lipid uptake. Alternatively, in vivo, multiple
factors can impact total surfactant pool size in addition to
clearance by inflammatory cells.
Type II cells are the predominant cell type that regulates
surfactant metabolism, being involved in synthesis,
secretion and clearance. Secretion of surfactant phosphol-
ipids is solely a property of alveolar type II cells, whereas
clearance in a healthy lung is regulated primarily by both
type II cells and alveolar macrophages. In one study utiliz-
ing uninjured rabbits, it was determined that type II cells
accounted for approximately 65% of the clearance of alve-
olar phospholipid [25]. In a situation of pulmonary
inflammation induced by LPS administration, there have
been documented decreases in alveolar surfactant phos-
pholipids [9-11], increases in intracellular surfactant
phospholipids [10] and the appearance of giant lamellar
bodies within type II cells [17,18,26]. From these observa-
tions, LPS induced inflammation could either inhibit sur-
factant secretion or enhance surfactant clearance by type II
cells, resulting in diminished alveolar surfactant pool and
increased intracellular pool. We originally hypothesized
that after LPS administration there was increased
clearance of surfactant phospholipids by type II cells.
However, data from this study demonstrated that in vivo,
surfactant clearance by type II cells was similar at both 18
and 72 hours after intrapulmonary LPS instillation com-
pared to control groups killed at the same time points
(Figs 4 and 5). Data from the current study cannot lead to
any conclusions pertaining to alterations in type II cell
phospholipid synthesis or secretion.
As mentioned, we observed a small but not statistically
significant decrease in alveolar phospholipid pools after
LPS administration, which is in contrast to previous stud-
ies by Viviano et al. and MacIntosh et al. that used 1 mg/
kg and 0.5 mg/kg of LPS respectively [9,10]. Nevertheless,
we did observe a similar increase in alveolar levels of SP-
A after intrapulmonary LPS (Fig 1), which is a well docu-
mented characteristic of lung inflammation after LPS
exposure [9-11]. This increase has been primarily attrib-
uted to increased SP-A synthesis by type II cells [11]
suggesting that indeed type II cell metabolism was altered
in our model. Additionally, these data provide further
experimental evidence that surfactant phospholipid and
SP-A pools can be independently regulated in response to
inflammatory agents.
We also investigated additional tissue-associated cells that
were isolated after lung digestion (primarily macrophages
and neutrophils). Similar to type II cells, surfactant clear-
ance from these tissue-associated cells isolated from the
two LPS groups were similar to their respective control
groups. In addition, the clearance attributed to type II cells
and tissue-associated cells was similar at both time points
for the LPS and control groups. This observation is in
agreement with a study by Gurel et al., that documented
that alveolar type II cells and tissue macrophages contrib-
uted equally to the alveolar clearance of phospholipid in
adult mice [27].
Conclusions
In conclusion, we demonstrated that after intrapulmo-
nary LPS administration in adult rats, the in vivo clearancePublish with BioMed Central    and   every 
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of surfactant lipids by type II cells is unaltered and that the
increased clearance of surfactant lipids is primarily due to
either neutrophils or macrophages that are recruited to
the alveolar space.
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